Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > RLYB Rallybio > Key Indicators
RLYB Rallybio
Post Mkt Price
Do not show
Hide blank lines
Financial Ratios
Efficiency Ratios TTM
-- -138.153% -- -91.619% -- -72.631% -- -72.631%
-- -139.367% -- -92.531% -- -72.563% -- -72.563%
-13.24% -39.674% -16.56% -32.297% 10.33% -29.016% 10.33% -29.016%
Efficiency Ratios
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- 0.323% -- 0.317% -- -- -- --
Total Assets to Common Equity
-- 105.246% -- 103.875% -- 103.749% -- 103.749%
Debt to Asset Ratio
-- 0.425% -- 0.408% -- -- -- --
Current Ratio
32.61% 21.2007 36.63% 28.9279 14.2% 27.6094 14.2% 27.6094
Quick Ratio
33.06% 20.2484 32.43% 27.8291 11.52% 26.7645 11.52% 26.7645
Growth Ratios
Currency Unit

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
CEO: MacKay Ph.D., Martin W.
Market: NASDAQ
Futu Hot List
SymbolLatest price%Chg


Back to the Top